Quite a few biotech commentators of late have been seeing...

Quite a few biotech commentators of late have been seeing evidence of big pharma divesting
themselves from R&D to concentrate on their revenue generating products....
R&D is seen as being left to the likes of Immutep but being closely monitored in the process....
This monitoring and any involvement is perceived to be taking place in 3 stages...
1....Collaborating, a foot in the door so to speak...
2....Progressing to partnerships to help fund ph2 trials or other....
3....Takeover, if and when considered to be a worthwhile revenue generating possibility.
We have partnerships but I consider them to be inherited partnerships but not negotiated
until after Prima takeover , in short current management were not involved...Frederic excepted..
Frederic is on record saying the selloff of IMP 701 and 731 was purely to fund IMP 321....

That brings us to Merck, this is big IMO....1st stage of above achieved......

Just my view...